BCL2L1 and neoplasm: Thus [ruxolitinib + MMF] treatment kills tumor cells through prolonged inactivation of multiple upstream protective signaling pathways which leads to lower levels of protective BH3 domain proteins (BCL-XL, MCL-1) and to higher levels of toxic activated BH3 domain proteins (BIM, BAD) which promotes mitochondrial dysfunction and ROS generation.